Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 16/20 | 0.46 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957911 | 0.92 | RIPK1 (0.44) | RIPK1NTRK1 | |
| SCHEMBL22957901 | 0.92 | RIPK1 (0.44) | RIPK1NTRK1 | |
| SCHEMBL22957671 | 0.89 | RIPK1 (0.44) | RIPK1GRM5 | |
| SCHEMBL24018824 | 0.88 | RIPK1 (0.41) | RIPK1 | |
| SCHEMBL24783238 | 0.84 | RIPK1 (0.43) | RIPK1NTRK1 | |
| SCHEMBL24180142 | 0.84 | RIPK1 (0.40) | RIPK1EIF4EMKNK1MKNK2GRM5 | |
| SCHEMBL22957895 | 0.84 | RIPK1 (0.43) | RIPK1NTRK1 | |
| SCHEMBL22957716 | 0.84 | RIPK1 (0.43) | RIPK1NTRK1 | |
| SCHEMBL22391506 | 0.84 | RIPK1 (0.40) | RIPK1EIF4EMKNK1MKNK2GRM5 | |
| SCHEMBL22957912 | 0.84 | RIPK1 (0.43) | RIPK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885EIF4E 814/4885MKNK1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.